Authors

Latest:

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.

Matthew J. Matasar, MD

Latest:

Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.

Matthew Kulke, MD

Latest:

Systemic Therapy: Advanced Neuroendocrine Tumors

After reviewing the goals of therapy in advanced NET management, Matthew H. Kulke, MD, considers optimal treatment selection and sequencing in this setting.

Matthew Ladra, MD

Latest:

Dr. Ladra on the Treatment of Pediatric Esthesioneuroblastoma

Matthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

Latest:

Practice Patterns and Real Use of Epcoritamab and Glofitamab

A panel of experts discuss the role of odronextamab.

Matthew Mahady

Latest:

As Practice Grows, Competitors Loom

Established just nine years ago via the merger of three specialty practices and 14 physicians, Dayton Physicians Network, an independent, Ohio-based oncology group practice, has experienced rapid growth, fueled in part by increased Medicaid enrollment and profits from their oral drug dispensing program.

Matthew P. Goetz, MD

Latest:

Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Matthew P. Goetz, MD, The Mayo Clinic

Matthew P. Schlumbrecht, MD

Latest:

Dr. Schlumbrecht on Treatment in Uterine Leiomyosarcoma

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

Matthew Powell, MD

Latest:

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Matthew Powell, MD, Washington University

Matthew Powell, MD, Washington University School of Medicine

Latest:

Practical Implications for Treatment Strategies in Advanced Ovarian Cancer

Matthew R. Cooperberg, MD, MPH

Latest:

Dr. Cooperberg on Ongoing Trials in Early Prostate Cancer

Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.

Matthew R. Smith, MD, PhD, Massachusetts General Hospital Cancer Center

Latest:

Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study

Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Matthew R. Zibelman, MD

Latest:

Dr. Zibelman on Managing Immune-Related Adverse Events

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).

Matthew S. Davids, MD

Latest:

Dr. Davids on the Potential Utility of Frontline Ibrutinib/Umbralisib in CLL and MCL

Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.

Matthew S. Davids, MD, Dana-Farber Cancer Institute

Matthew S. Davids, MD, MMSc

Latest:

Clinical Pearls and Impacts to Practice from EHA 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Matthew S. Davids, MD, MMSc, Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute

Matthew S Davids, MD, MMSc, Dana-Farber Cancer Institute